Publications
94
Citations
1,347
Est. group size
~24
Recurring co-author estimate
Active years
17
Publishing since 2009
Sagar Sardesai's research focuses on clinical trials and treatment strategies for breast cancer, particularly hormone receptor-positive and triple-negative subtypes. Work includes studies of new drugs (such as CDK7 inhibitors, PIK3CA inhibitors, and antibody-drug conjugates) and the use of blood-based tumor DNA testing to monitor cancer during treatment. Much of the research involves multi-site clinical trials reported at major oncology conferences and journals.
Publication output has grown substantially since 2018, rising from just 1-2 papers per year to a sustained pace of roughly 9-16 papers annually over the past five years, with continued high activity through 2025.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Circulating tumor (ct)DNA monitoring of ER+/HER2- high-risk breast cancer during adjuvant endocrine therapy.
Journal of Clinical Oncology · 2025
- Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib
Nature Communications · 2025
- Acolbifene vs tamoxifen for breast cancer prevention in premenopausal women at high risk for breast cancer.
Journal of Clinical Oncology · 2025
- Abstract P5-08-13: Real-world demographics, clinical characteristics, and treatment patterns among US patients with HER2-negative early breast cancer and germline BRCA mutations since 2021
Clinical Cancer Research · 2025
- Abstract PS06-02: Circulating tumor DNA (ctDNA) monitoring of estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) high risk breast cancer during adjuvant endocrine therapy
Cancer Research · 2024
- Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib
Nature Communications · 2023
- Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib
Nature Communications · 2023
- Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer
Breast Cancer Research and Treatment · 2022
- Abstract GS3-10: Study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced hormone receptor positive HER2 negative breast cancer (HR+BC)
Cancer Research · 2022
- Abstract P5-16-15: Post-progression therapy outcomes in patients (pts) from the phase 3 ASCENT study of sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC)
Cancer Research · 2022
- Targeting insulin feedback to enhance alpelisib (TIFA): A phase II randomized trial in metastatic, <i>PIK3CA</i>-mutant, hormone receptor–positive breast cancer.
Journal of Clinical Oncology · 2022
- Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer
Annals of Oncology · 2021
- Treating Alpelisib-Induced Hyperglycemia with Very Low Carbohydrate Diets and Sodium-Glucose Co-Transporter 2 Inhibitors: A Case Series
Integrative Cancer Therapies · 2021
- 265P Study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced hormone receptor positive HER2 negative breast cancer (HR+BC)
Annals of Oncology · 2021
- 258P Analysis of patients (pts) without an initial triple-negative breast cancer (TNBC) diagnosis (Dx) in the phase III ASCENT study of sacituzumab govitecan (SG) in brain metastases-negative (BMNeg) metastatic TNBC (mTNBC)
Annals of Oncology · 2021
- Journal of Clinical Oncology×16
- Cancer Research×14
- Clinical Cancer Research×5
- Annals of Oncology×4
- Nature Communications×3
- Preeti Sudheendra
Medicine · The Ohio State University
- Gilbert Bader
Medicine · The Ohio State University
- Patrick Schnell
Medicine · The Ohio State University
- Robert Wesolowski
Medicine · The Ohio State University
- Mathew Cherian
Biochemistry, Genetics and Molecular Biology · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile